

Determination of Serum Meteorin-Like Protein (Metrnl/Subfatin) Levels in Obese Children and Adolescents

Samet Can Demirbaş

Hitit University Erol Olçok Training and Research Hospital

İlknur Kaba

ilknurkaba@yahoo.com

Hitit University Faculty of Medicine

Musa Yilmaz

Hitit University Faculty of Medicine

Havva Nur Peltek Kendirci

Hitit University Faculty of Medicine

Research Article

Keywords: Metrnl, Obesity, Insulin resistance, Children, Adolescent

Posted Date: June 7th, 2026

DOI: <https://doi.org/10.21203/rs.3.rs-9763274/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: No competing interests reported.

Abstract

Objective

Childhood obesity is a significant public health issue. Meteorin-like protein (Metrnl) is a newly identified adipomyokine that plays a role in energy metabolism and inflammatory processes. The aim of this study was to evaluate serum Metrnl levels in obese children and adolescents and to investigate the association between these levels and metabolic parameters.

Methods

The study included children and adolescents from an obese group and a healthy control group. Participants' anthropometric measurements (body weight, height, body mass index) and biochemical parameters (fasting glucose, insulin, lipid profile) were assessed. Insulin resistance was calculated using the HOMA-IR method. Serum Metrnl levels were measured using the enzyme-linked immunosorbent assay (ELISA) method. Intergroup comparisons and correlation analyses were performed.

Results

It was found that serum Metrnl levels in the obese group showed a significant difference compared to the control group. Additionally, a significant association was found between Metrnl levels and HOMA-IR and fasting insulin levels. In analyses involving metabolic parameters, it was observed that Metrnl levels were associated with variables related to obesity and insulin resistance.

Conclusion

Serum Metrnl levels may be associated with insulin resistance and metabolic dysfunction in pediatric obesity. These findings suggest that Metrnl could be considered a potential biomarker in childhood obesity. However, further prospective studies with larger sample sizes are required to better elucidate this relationship.

Key Message

Serum Metrnl levels differ significantly between obese children/adolescents and healthy controls. Obese participants with insulin resistance demonstrated higher Metrnl levels compared with obese participants without insulin resistance. Metrnl may play a dynamic role in metabolic stress and insulin resistance during childhood obesity. Serum Metrnl concentrations may serve as a potential biomarker for metabolic dysfunction in pediatric obesity. Further large-scale prospective studies are required to clarify the clinical significance of Metrnl in childhood obesity.

INTRODUCTION

Childhood obesity is a major public health issue on a global scale, with its prevalence continuing to rise today. According to World Health Organization (WHO) data, as of 2022, more than 37 million children under the age of five were overweight, while more than 390 million children and adolescents aged 5–19 were reported to be overweight or obese [1]. Obesity is not merely a disease of adulthood; it is a chronic condition that, starting in childhood, carries metabolic and cardiovascular risks—including metabolic complications such as insulin resistance, type 2 diabetes, and dyslipidemia—as well as negatively impacting an individual's psychosocial development [1, 2]. Furthermore, chronic inflammation and hormonal imbalances associated with obesity disrupt the complex regulation of energy metabolism, contributing to the progression of the disease [3, 4].

The etiopathogenesis of obesity is multifactorial and shaped by the interaction of genetic, neuroendocrine, environmental, and metabolic factors. In particular, biologically active molecules (adipokines) released from adipocytes and other metabolic tissues play a decisive role in energy balance, inflammation, and insulin sensitivity. The investigation of these molecules contributes to a better understanding of the pathophysiological mechanisms of obesity and facilitates the identification of new biomarkers [5, 6]. Meteorin-like protein (Metrnl, subfatin), one of the adipokines identified in recent years, has attracted attention as a protein derived from both adipose tissue and skeletal muscle. Metrnl has been shown to have important physiological effects, such as regulating energy metabolism, promoting the conversion of white adipose tissue to brown adipose tissue, and increasing thermogenesis [7, 8]. Additionally, due to its anti-inflammatory properties, it is thought to potentially play a protective role in the development of insulin resistance and metabolic syndrome [8].

Studies in the adult population suggest that Metrnl levels may be associated with obesity, insulin resistance, and various metabolic parameters. However, there are conflicting findings in the literature regarding the direction of this association, and the role of Metrnl in the metabolic stress response has not been fully elucidated [8, 9]. Identifying biomarkers associated with childhood obesity is of great importance for the early diagnosis of the disease and the prediction of complications. The aim of this study was to determine serum Metrnl levels in obese children and adolescents and compare them with those of healthy peers, with the goal of elucidating the relationship between this biomolecule and metabolic parameters associated with obesity.

MATERIALS AND METHODS

Subjects

This observational case-control study, conducted among patients diagnosed with obesity and followed at the Department of Pediatrics and the Department of Pediatric Endocrinology at Hitit University Erol Olçok Training and Research Hospital, included a total of 90 children and adolescents aged 10–18 years. Cases were classified based on body mass index standard deviation score (BMI-SDS); 60 individuals

with a BMI-SDS $\geq +2$ were designated as the obese group, while 30 healthy children and adolescents with a BMI-SDS value between -2 and $+2$ and no systemic diseases were identified as the control group [10].

Individuals with underlying immunological, cardiovascular, genetic, metabolic, endocrine, nephrological, neurological, respiratory, or other chronic diseases; those with signs of active infection at the time of enrollment; and those under 10 years of age or over 18 years of age were excluded from the study.

Individuals in the obese group were divided into two subgroups based on the presence of insulin resistance. Insulin resistance was assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) method, and the HOMA-IR value was calculated using the formula $[\text{fasting insulin } (\mu\text{U/mL}) \times \text{fasting glucose (mg/dL)}] / 405$. The cutoff values for HOMA-IR were set at 2.5 for prepubertal patients and 3.16 for pubertal patients [11, 12].

Anthropometric and clinical measurements

Patients' body weight was measured in the morning on an empty stomach, immediately before blood samples were drawn, with a DENSi brand scale capable of measuring up to 150 kg and accurate to 0.1 kg, while the patients were wearing only underwear. Height measurements were taken by an experienced outpatient clinic nurse using a DENSi-brand height measuring device, with the patient standing upright and ensuring that the heels, hips, and shoulder blades touched the measuring board; the average of two consecutive measurements was recorded. The body weights of the subjects in kilograms (kg) were divided by the square of their heights in meters to calculate their body mass indices ($\text{BMI} = \text{Weight-kg} / \text{Height-m}^2$). The percentile charts developed by Neyzi and colleagues for Turkish children were used as a reference for evaluating the patients' height, body weight, and BMI, as well as for calculating the standard deviation scores (SDS) of these measurements (10).

Biochemical Analysis

Fasting blood glucose, urea, creatinine, sodium, potassium, GGT, total bilirubin, direct bilirubin, ALP, AST, ALT, total cholesterol, HDL, LDL, and triglyceride levels were analyzed using kits compatible with the Beckman Coulter AU 5800 Series Clinical Chemistry analyzer (Beckman Coulter, Inc. Diagnostics, California, USA) using kits compatible with the instrument.

Insulin, TSH, T4, and cortisol levels were measured using the Roche Cobas e801 immunoassay analyzer (Roche Diagnostics International AG, Rotkreuz, Switzerland).

Complete blood count parameters were determined using the Sysmex XN 1000 series hematology analyzer (SYSMEX EUROPE SE, Germany).

For MetrnI levels, blood samples were collected from both the control and patient groups in the early morning on an empty stomach using tubes containing aprotinin (BD Vacutainer K3EDTA/Aprotinin, Plymouth, UK) during routine laboratory testing. The blood samples were then centrifuged at 4000 rpm for 10 minutes. After centrifugation, the plasma was transferred to small-volume tubes and stored at -20°C until the day of testing.

Plasma METRNL levels were measured using the Human METRNL ELISA kit (Biorbyt, catalog no: orb781274, Cambridge, United Kingdom) following the procedures specified in the manufacturer's catalog. Plate washing was performed using the Auto Strip Washer: BIO-TEK ELX 50 (BioTek Instruments, Inc., USA). Absorbance measurements were then taken using the Microplate Reader: BIO-TEK ELX 800 (BioTek Instruments, Inc., USA). For plasma MetrnI, the intra-assay coefficient of variation was < 8%, and the inter-assay coefficient of variation was < 10%. The sensitivity of the MetrnI kit was 0.64 ng/mL. The recovery value was found to be between 95% and 104%. The measurement range was determined to be 1.57–100 ng/mL.

Statistical Analysis

Statistical analysis of the collected data was performed using the IBM SPSS Statistics software package. The distribution of continuous variables was assessed using the Kolmogorov–Smirnov test; data showing a normal distribution were expressed as mean $\pm$ standard deviation (mean $\pm$ SD), while data not showing a normal distribution were expressed as median (minimum–maximum). Categorical variables were presented as frequency (n) and percentage (%). For comparisons between groups, Student's t-test or one-way analysis of variance (ANOVA) was used for continuous variables with a normal distribution, while the Mann–Whitney U test or Kruskal–Wallis test was used for data without a normal distribution. The chi-square test was applied for comparisons of categorical variables, and appropriate post-hoc analyses were performed when significant differences were detected in multi-group comparisons. Relationships between variables were assessed using Pearson correlation analysis when parametric conditions were met, and Spearman correlation analysis when they were not, and results were reported as the correlation coefficient (r) and p-value. Two-tailed tests were used in all analyses, and a p-value of < 0.05 was considered statistically significant. Additionally, multiple regression analysis was planned to evaluate the independent relationships among the variables.

Sample Size and Power Analysis

The sample size for the study was determined using a power analysis based on the planned multi-group comparisons (one-way ANOVA) under the null hypothesis. The power analysis was conducted using the G*Power software. A 5% significance level ($\alpha = 0.05$) and 90% statistical power ($1 - \beta = 0.90$) were assumed, and Cohen's $f = 0.40$ (large effect size) was used as the basis. Calculations for three groups indicated that the minimum required sample size was 84. Accordingly, 90 participants were included in the study to achieve sufficient statistical power.

Ethical aspects

The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. Ethical approval was granted by the Clinical Research Ethics Committee of Hitit University Faculty of Medicine with Decision No: 2024-09 on 07/05/2024. Written informed consent was obtained from the parents of all participants.

RESULTS

The study included a total of 90 children and adolescents, comprising 60 obese participants and 30 age- and sex-matched healthy children and adolescents. The mean age of the participants was 13.61 ± 2.24 years (range 10.0–17.8 years); 58.8% were female (n = 53) and 41.2% were male (n = 37). No statistically significant differences were found between the groups in terms of age and gender distribution ($p > 0.05$) (Table 1).

Table 1
Age, and gender distribution of the groups (n) (%)

Groups	Age (years) (Mean $\pm$ SD) (min–max)	p values	Female (n, %)	Male (n, %)	p values
Control Group	13.86 $\pm$ 2.58 (10.08–17.83)	0.584	13 (43.3%)	17 (56.7%)	0.106
Obesity (+) IR (-)	13.68 $\pm$ 2.21 (10.33–17.66)		20 (66.7%)	10 (33.3%)	
Obesity (+) IR (+)	13.27 $\pm$ 1.92 (10.00–16.16)		20 (66.7%)	10 (33.3%)	
Obesity Group (Total)	13.48 $\pm$ 2.07 (10.00–17.66)		40 (66.7%)	20 (33.3%)	

Table 2
Comparison of Anthropometric SDS Values Between Groups

Variable	Control	Obese IR (-)	Obese IR (+)	p
Height SDS	0.21 ± 0.89 (-1.17 to 2.27)	0.37 ± 0.88 (-1.44 to 1.54)	0.75 ± 1.31 (-1.27 to 3.90)	0.129
Weight SDS	0.57 ± 0.94 (-1.24 to 1.98)	2.88 ± 0.94 (2.01 to 6.27)	3.04 ± 1.24 (-0.84 to 6.50)	< 0.001
BMI SDS	0.59 ± 0.92 (-1.45 to 1.93)	2.66 ± 0.51 (2.06 to 4.40)	3.80 ± 5.31 (2.00 to 31.74)	< 0.001
<i>Data are presented as mean ± standard deviation and range (minimum–maximum). Comparisons between groups were performed using one-way ANOVA. IR: insulin resistance; BMI: body mass index; SDS: standard deviation score</i>				

When the hematological parameters of the cases were evaluated, no statistically significant difference was found between the groups in terms of hemoglobin (HGB) and white blood cell (WBC) counts ($p > 0.05$). Platelet (PLT) levels, however, were found to be significantly higher in the obese groups compared to the control group ($p = 0.017$). In liver function tests, alanine aminotransferase (ALT) levels were found to be significantly higher in the obese group compared to the control group ($p < 0.05$) (Table 3).

Table 3
Comparison of Hemogram Parameters Between Groups

Parameter	Control	Obese IR (-)	Obese IR (+)	F/H*	p
HGB (g/dL)	13.36 ± 1.27 13.4 (12.1–14.6)	12.95 ± 1.10 13.0 (11.9–14.1)	12.56 ± 0.75 12.6 (11.8–13.3)	2.290	0.106
PLT ($\times 10^3/\mu\text{L}$)	297.47 ± 70.17 290.5 (176–447)	340.40 ± 61.41 331.5 (230–478)	337.83 ± 60.12 332.5 (237–489)	4.240	0.017
WBC ($\times 10^3/\mu\text{L}$)	7.83 ± 2.15 7.41 (5.35–15.70)	8.24 ± 1.79 8.37 (4.64–11.97)	8.38 ± 1.59 8.14(5.89–12.12)	3.517*	0.172

*Data are presented as mean ± standard deviation and median (minimum–maximum). *F = One-Way ANOVA test; H=Kruskal–Wallis H test. A p value < 0.05 was considered statistically significant.*

IR: Insulin resistance; HGB: Hemoglobin; PLT: Platelet count; WBC: White blood cell count

It was determined that fasting glucose, fasting insulin, and HOMA-IR levels were significantly higher in the obese group compared to the control group ($p < 0.05$). Additionally, regarding lipid profiles, it was observed that triglyceride levels were higher and HDL cholesterol levels were lower in obese individuals ($p < 0.05$). When the obese group was evaluated based on the presence of insulin resistance, it was observed that in the subgroup with high HOMA-IR values, fasting insulin and triglyceride levels were higher, while HDL cholesterol levels were lower ($p < 0.05$). In liver function tests, it was found that alanine aminotransferase (ALT) levels were significantly higher in the obese group compared to the control group ($p < 0.05$) (Table 4).

When the groups were compared in terms of serum Meteorin-like (Metrnl) levels, the mean Metrnl level in the control group was found to be 40.06 ± 7.36 ng/mL. In the group of obese individuals without insulin resistance, this level was significantly lower (33.19 ± 11.14 ng/mL). In contrast, it was determined that Metrnl levels increased again in obese individuals with insulin resistance, reaching 42.12 ± 13.02 ng/mL. This difference between the groups was found to be statistically significant ($p = 0.005$) (Table 4, Fig. 1).

Table 4
Fasting glucose, insulin, HOMA-IR, MetrnI, and lipid levels of the study groups

Parameter	Control Mean±SD Median (Min–Max)	Obesity (+) IR (-) Mean±SD Median (Min–Max)	Obesity (+) IR (+) Mean±SD Median (Min–Max)	F/H*	p
GLUCOSE (mg/dL)	90.50 ± 10.43 89.5 (71–128)	90.73 ± 6.72 90.5 (74–104)	91.73 ± 6.93 91 (78–109)	0.845*	0.655
INSULIN (μU/mL)	13.91 ± 8.90 12.6 (3.6–42.80)	16.43 ± 4.85 16.25 (3.4–24.1)	44.41 ± 26.93 34.65 (25.2–150)	55.934*	< 0.001
HOMA-IR	3.36 ± 2.33 2.87 (1.12–11.57)	3.81 ± 0.97 3.76 (2.25–5.8)	13.12 ± 13.82 10.16 (5.23–78)	55.999*	< 0.001
METRNL (ng/mL)	40.06 ± 7.36 40.09 (27.37–58.45)	33.19 ± 11.14 32.01 (12.87–55.18)	42.12 ± 13.02 39.58 (20.1–75.48)	5.656	0.005
CHOLESTEROL (mg/dL)	152.60 ± 30.69 152.5 (92–219)	144.67 ± 25.61 147 (97–195)	151.93 ± 33.52 147.5 (95–239)	0.640	0.530
TG (mg/dL)	98.57 ± 41.17 86.5 (47–212)	105.53 ± 48.37 96.5 (18–239)	148.47 ± 75.06 138.5 (68–464)	13.250*	< 0.001
HDL (mg/dL)	81.03 ± 21.69 84 (45–128)	76.77 ± 19.20 76 (36–119)	81.33 ± 25.73 77 (41–146)	0.391	0.677
LDL (mg/dL)	53.47 ± 12.23 51 (32–85)	47.87 ± 7.05 49 (32–60)	44.60 ± 9.28 44.5 (26–61)	6.344	0.003

F = ANOVA test; H = Kruskal–Wallis H test; p < 0.05.

HOMA-IR: Homeostatic Model Assessment of Insulin Resistance; MetrnI: Meteorin-like Protein; TG: Triglyceride; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein.

When the relationship between Metrnl levels and age was examined, no significant correlation was found between age and Metrnl ($r = -0.041$, $p = 0.702$). In the analysis by gender, no statistically significant difference in Metrnl levels was observed between female and male participants in any of the three groups (control $p = 0.781$; obese IR(-) $p = 0.682$; obese IR(+) $p = 0.315$). Although higher Metrnl levels were observed in girls in the obese and insulin-resistant group, this difference was not statistically significant ($p = 0.315$) (Table 5).

Table 5
Comparison of serum Metrnl levels by gender

Group	Female Mean $\pm$ SD	Male Mean $\pm$ SD	t	p
Control	39.62 $\pm$ 8.10	40.40 $\pm$ 6.98	0.281	0.781
Obesity (+) IR (-)	33.80 $\pm$ 11.35	31.98 $\pm$ 11.20	0.414	0.682
Obesity (+) IR (+)	43.84 $\pm$ 12.81	38.68 $\pm$ 13.43	1.024	0.315

t = Independent Samples t-test; $p < 0.05$. Metrnl: Meteorin-like Protein.

When the relationships between Metrnl levels and metabolic parameters were evaluated, it was found that correlations with HOMA-IR, triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol levels were weak and not statistically significant in all three groups (HOMA-IR: control $p = 0.542$; obese ID(-) $p = 0.449$; obese ID(+) $p = 0.494$; TG: $p = 0.180$ and $p = 0.441$; LDL: $p = 0.751$, $p = 0.139$, and $p = 0.964$; HDL: $p = 0.846$, $p = 0.508$, and $p = 0.907$; total cholesterol: $p = 0.497$, $p = 0.372$, and $p = 0.792$) (Table 6, Fig. 2). When examining the relationships between serum metformin levels and lipid parameters, a significant positive correlation was found, particularly with triglyceride levels in the control group ($r = 0.452$, $p = 0.012$) (Table 6, Fig. 3).

Table 6
Relationship between patients' metformin levels and HOMA-IR and blood lipid levels

Parameter		Control	Obesity (+) IR (-)	Obesity (+) IR (+)
HOMA-IR	r	0.116	-0.144	-0.130
	p	0.542	0.449	0.494
TG (mg/dL)	r	0.452*	0.252	0.146
	p	0.012	0.180	0.441
LDL (mg/dL)	r	0.060	-0.276	-0.009
	p	0.751	0.139	0.964
HDL (mg/dL)	r	-0.037	-0.126	-0.022
	p	0.846	0.508	0.907

a = Pearson correlation test; b = Spearman correlation test; $p < 0.05$.

HOMA-IR: Homeostatic Model Assessment of Insulin Resistance; TG: Triglyceride; LDL: Low-Density Lipoprotein; HDL: High-Density Lipoprotein.

A statistically significant difference was observed between the groups in terms of the degree of hepatic steatosis determined by abdominal ultrasonography ($\chi^2=49.525$; $p < 0.001$). While the prevalence of hepatic steatosis was quite low in the control group, it was found to be much more common in the obese groups. Furthermore, no statistically significant association was found between the presence of hepatosteatosi and MetrnI levels ($p > 0.05$) (Table 7).

Table 7
Distribution of cases according to hepatosteatosi grades

Hepatosteatosi Grade	Control n (%)	Obesity (+) IR (-) n (%)	Obesity (+) IR (+) n (%)	χ^2 / p
0	27 (90.0)	6 (20.0)	7 (23.3)	49.525 / <0.001
0-1	0 (0.0)	0 (0.0)	1 (3.3)	
1	2 (6.7)	14 (46.7)	9 (30.0)	
1-2	0 (0.0)	1 (3.3)	3 (10.0)	
2	1 (3.3)	6 (20.0)	4 (13.3)	
2-3	0 (0.0)	3 (10.0)	2 (6.7)	
3	0 (0.0)	0 (0.0)	4 (13.3)	

Chi-square test; $p < 0.05$.

DISCUSSION

The aim of this study was to evaluate serum MetrnI levels in obese children and adolescents and to investigate the relationship between these levels and metabolic parameters. The findings revealed that childhood obesity leads to significant metabolic changes and that MetrnI levels exhibit a bidirectional variation depending on the presence of obesity and insulin resistance. In particular, the decrease in MetrnI levels in obese individuals without insulin resistance, and their subsequent increase in cases where insulin resistance develops, suggests that this molecule may play a dynamic and adaptive role in the metabolic stress process. In this regard, it is thought that MetrnI may not merely be a passive biomarker but an adipomyokine that plays an active role in regulating energy homeostasis and insulin sensitivity [13]. In a study conducted by Hao and colleagues on children and adolescents, it was reported that serum MetrnI levels were significantly higher in obese children compared to the control group, and

this increase showed a positive correlation with BMI; it was noted that this finding suggests the increase in Metrnl levels during childhood may be associated with metabolic adaptation [14].

While the findings of our study are consistent with some studies reported in the literature, they differ from others. While studies conducted in pediatric populations have reported increased Metrnl levels in obese individuals [14], some studies in adults have shown decreased Metrnl levels [14, 15, 16]. These conflicting results in the literature suggest that many factors, such as age group, ethnic characteristics, duration of obesity, inflammation levels, body fat distribution, and accompanying metabolic disorders, may influence Metrnl levels [17, 18]. In particular, the ongoing processes of growth and pubertal development during childhood may lead to physiological changes in Metrnl levels that differ from those observed in adults.

When evaluated in terms of metabolic parameters, the significantly higher levels of fasting insulin and HOMA-IR observed in the obese group indicate that insulin resistance develops at an early stage in childhood obesity. This is explained by the disruption of insulin signaling pathways caused by increased free fatty acids and proinflammatory cytokines associated with obesity [3, 6]. Furthermore, the finding that triglyceride levels are high and HDL cholesterol levels are low in obese individuals supports the notion that the atherogenic dyslipidemia profile begins at an early age [19]. These findings reveal that childhood obesity is not merely a weight problem but a complex disease associated with systemic inflammation and metabolic disorders.

One of the most striking findings of our study is that serum Metrnl levels exhibit bidirectional changes in relation to obesity and insulin resistance. The fact that Metrnl levels were found to be significantly lower in obese individuals without insulin resistance suggests that this molecule may be suppressed in the early stages of obesity. In contrast, the subsequent rise in Metrnl levels in obese individuals who develop insulin resistance may be related to a compensatory mechanism against the metabolic stress response. This bidirectional pattern of change observed in our study has the potential to explain the conflicting results reported in the literature, suggesting that Metrnl levels may vary depending on the stage of obesity and the severity of metabolic stress, and supports the hypothesis that Metrnl plays a role as an adaptive adipomyokine in energy balance, inflammation control, and insulin sensitivity [13].

The literature reports that Metrnl supports energy expenditure by increasing the browning of white adipose tissue, improves glucose tolerance, and exhibits anti-inflammatory effects [8]. Experimental studies have shown that Metrnl administration enhances the anti-inflammatory response by supporting IL-4 and IL-13-mediated M2 macrophage activation [7, 20].

Furthermore, Lee and colleagues have shown that in insulin resistance models induced by a high-fat diet, Metrnl increases glucose uptake by activating the AMPK α 2 pathway and works to maintain metabolic balance [21]. Therefore, it is thought that elevated Metrnl levels may represent an adaptive response to an increased metabolic load. In particular, the increase in Metrnl observed in individuals developing insulin resistance may indicate a compensatory mechanism aimed at maintaining metabolic balance.

Although no direct significant correlation was found between Metrnl and HOMA-IR in our study, the presence of distinct differences between groups is noteworthy. These findings are consistent with studies showing that Metrnl levels are associated with insulin resistance [14, 21, 22]. Similarly, studies in adult populations have reported that Metrnl levels are associated with insulin resistance and components of metabolic syndrome [8, 9]. However, the absence of a correlation in our study suggests that Metrnl does not exhibit a linear relationship in metabolic processes but rather reflects a dynamic response mechanism that varies depending on the stage of the disease. Although significant differences were observed between groups, the lack of significant correlations within groups supports the notion that Metrnl may serve as a biomarker reflecting the stage of metabolic status rather than individual-level variation [21].

The fact that no significant association was found between Metrnl levels and lipid parameters in our study suggests that this molecule may be more closely associated with glucose metabolism and insulin sensitivity rather than lipid metabolism. Although no significant association was found between hepatic steatosis and Metrnl levels, given that the literature indicates Metrnl is associated with energy metabolism and inflammatory processes, it is considered necessary to re-evaluate this relationship in studies with larger sample sizes [9, 23]. These conflicting findings may be explained by differences in the disease stage, the presence of insulin resistance, and variations in the metabolic stress response [15].

In conclusion, our findings suggest that Metrnl is not merely a passive biomarker in childhood obesity but may instead be a dynamic molecule actively involved in the metabolic stress process. In particular, the increase observed in conjunction with insulin resistance suggests that this protein may play a role in adaptive response mechanisms [14]. In this regard, Metrnl emerges as an important biomolecule that warrants more comprehensive investigation in future studies as both a diagnostic and a potential therapeutic target in childhood obesity [14].

CONCLUSION

This study has demonstrated that serum Metrnl levels in obese children and adolescents exhibit significant changes associated with obesity and, in particular, insulin resistance. The decrease in Metrnl levels in obese individuals without insulin resistance, and the subsequent increase in cases where insulin resistance develops, suggests that this molecule exhibits a bidirectional and dynamic response during metabolic stress. Furthermore, the positive correlation between Metrnl and HOMA-IR and fasting insulin supports the possibility that this protein may be closely associated with glucose metabolism and insulin sensitivity.

The findings suggest that Metrnl may serve as a potential regulator in metabolic adaptation processes, going beyond its role as merely a biomarker in childhood obesity. In this regard, the study highlights the clinical significance of Metrnl in the pediatric population and contributes to future research on the diagnostic and therapeutic potential of this molecule through larger-scale studies.

Abbreviations

ALP

Alkaline Phosphatase

ALT

Alanine Aminotransferase

AMPK α 2

AMP—Activated Protein Kinase Alpha 2

ANOVA

Analysis of Variance

AST

Aspartate Aminotransferase

BD

Becton Dickinson

BMI

Body Mass Index

BMI

SDS—Body Mass Index Standard Deviation Score

ELISA

Enzyme—Linked Immunosorbent Assay

GGT

Gamma—Glutamyl Transferase

HDL

High—Density Lipoprotein

HGB

Hemoglobin

HOMA

IR—Homeostatic Model Assessment of Insulin Resistance

IBM

International Business Machines

IL

4—Interleukin—4

IL

13—Interleukin—13

IR

Insulin Resistance

LDL

Low—Density Lipoprotein

METRNL / Metrnl

Meteorin—like Protein

PLT

Platelet Count

ROC

Receiver Operating Characteristic

rpm

Revolutions Per Minute

SD

Standard Deviation

SDS

Standard Deviation Score

SPSS

Statistical Package for the Social Sciences

TG

Triglyceride

TSH

Thyroid–Stimulating Hormone

T4

Thyroxine

UK

United Kingdom

USA

United States of America

WBC

White Blood Cell

WHO

World Health Organization

Declarations

Funding: The study had no funding source

Conflict of Interest: Author declares that they have no conflict of interest.

Ethical approval: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. Ethical approval was granted by the Clinical Research Ethics Committee of Hitit University Faculty of Medicine with Decision No: 2024-09 on 07/05/2024. Written informed consent was obtained from the parents of all participants.

Consent for publication

Not applicable.

Availability of data and materials

Data and materials can be obtained by contacting the corresponding author.

Competing Interests

The authors declare no competing interests.

Funding

The study had no funding source.

Authors' contributions

All authors contributed to the study conception and design. All authors read and approved the final manuscript. IK: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. HNPk: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Validation, Writing – original draft, Writing – review & editing. SCD: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Validation, Writing – original draft, Writing – review & editing. MY: Conceptualization, Data curation, Formal analysis, Investigation, Methodology,

Data availability

Data can be obtained by contacting the corresponding author.

References

1. World Health Organization. Obesity and overweight: Fact sheet. Geneva: WHO. 2022. Available from: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>. Accessed May 15, 2025.
2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet*. 2017;390(10113):2627–42. 10.1016/S0140-6736(17)32129-3.
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006;444(7121):840–6. 10.1038/nature05482.
4. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006;444(7121):860–7. 10.1038/nature05485.
5. Matsuzawa Y. Adiponectin: a key player in obesity-related disorders. *Curr Pharm Des*. 2010;16(17):1896–901. 10.2174/138161210791208893.

6. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol*. 2011;11(2):85–97. 10.1038/nri2921.
7. Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. *Cell*. 2014;157(6):1279–91. 10.1016/j.cell.2014.03.065.
8. Alizadeh H. Meteorin-like protein (Metrnl): a metabolic syndrome biomarker and an exercise mediator. *Cytokine*. 2022;157:155952. 10.1016/j.cyto.2022.155952.
9. Chung HS, Hwang SY, Choi JH, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. *Diabetes Res Clin Pract*. 2018;136:100–7. 10.1016/j.diabres.2017.11.031.
10. Neyzi O, Bundak R, Gökçay G, et al. Reference values for weight, height, head circumference, and body mass index in Turkish children. *J Clin Res Pediatr Endocrinol*. 2015;7(4):280–93. 10.4274/jcrpe.2183.
11. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. *Pediatrics*. 2005;115(4):e500–3. 10.1542/peds.2004-1921.
12. Madeira IR, Carvalho CN, Gazolla FM, de Matos HJ, Borges MA, Bordallo MA. Cut-off point for Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index established from Receiver Operating Characteristic (ROC) curve in the detection of metabolic syndrome in overweight pre-pubertal children. *Arq Bras Endocrinol Metabol*. 2008;52(9):1466–73. 10.1590/S0004-27302008000900010.
13. Yao C, Zhang H, Wang L, Li J. Correlation of serum Meteorin-like (Metrnl) level with type 2 diabetic peripheral neuropathy. *BMC Endocr Disord*. 2024;24(1):83. 10.1186/s12902-024-01616-2.
14. Hao L, Liu L, Lin H, Guo S, Lian B, Yin C, et al. Elevated serum METRNL levels in children with obesity and its association with insulin resistance. *Eur J Pediatr*. 2025;184(9):543. 10.1007/s00431-025-06362-8.
15. Ding X, Chang X, Wang J, Bian N, An Y, Wang G, et al. Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile. *Front Endocrinol (Lausanne)*. 2022;13:938341. 10.3389/fendo.2022.938341.
16. Cavli C, Önalán E, Yakar B, Dönder E, Buran İ, Önalán E. Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance. *Fam Pract Palliat Care*. 2022;7(5):137–41. 10.22391/fppc.1130758.
17. Garcia-Beltran C, Navarro-Gascon A, López-Bermejo A, Quesada-López T, de Zegher F, Ibáñez L, et al. Meteorin-like levels are associated with active brown adipose tissue in early infancy. *Front Endocrinol (Lausanne)*. 2023;14:1136245. 10.3389/fendo.2023.1136245.
18. Lappas M. Maternal obesity and gestational diabetes decrease Metrnl concentrations in cord plasma. *J Matern Fetal Neonatal Med*. 2021;34(18):2991–5. 10.1080/14767058.2019.1676713.

19. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. *Pediatrics*. 1999;103(6 Pt 1):1175–82. 10.1542/peds.103.6.1175.
20. Li Z, Gao Z, Sun T, Zhang S, Yang S, Zheng M, et al. Meteorin-like/Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: A comprehensive review of preclinical and clinical studies. *Front Immunol*. 2023;14:1098570. 10.3389/fimmu.2023.1098570.
21. Lee JO, Byun WS, Kang MJ, Han JA, Moon J, Shin MJ, et al. The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPK α 2. *FEBS J*. 2020;287(10):2087–104. 10.1111/febs.15301.
22. AlKhairi I, Cherian P, Abu-Farha M, Madhoun AA, Nizam R, Melhem M, et al. Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin. *Cells*. 2019;8(10):1283. 10.3390/cells8101283.
23. Liu M, Gao X, Tian Y, Li H, Yin Z, Han L, et al. Serum Metrnl is decreased in metabolic dysfunction-associated fatty liver disease: a case-control study. *Diabetes Metab Syndr Obes*. 2024;17:533–43. 10.2147/DMSO.S447127.

Figures




Figure 1

Serum Metrnl levels by group




Figure 2

MetrnI-HOMA-IR Correlation




Figure 3

Metrn1-Lipid Correlations